nadolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
beta-adrenoreceptor antagonists	1865	42200-33-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nadolol corgard anabet solgol	A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor. Molecular weight: 309.41 Formula: C17H27NO4 CLOGP: 0.38 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 81.95 ALOGS: -2.14 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nadolol
corgard
anabet
solgol

A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.

Molecular weight: 309.41
Formula: C17H27NO4
CLOGP: 0.38
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 81.95
ALOGS: -2.14
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.16	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.25 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	73 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	34.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.14 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 10, 1979	FDA	KING PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	932.65	15.07	293	11672	24083	63452974
Chronic sinusitis	195.54	15.07	78	11887	12765	63464292
Paraesthesia oral	159.03	15.07	76	11889	19180	63457877
Procedural pain	150.84	15.07	76	11889	21493	63455564
Neovascularisation	148.48	15.07	36	11929	1109	63475948
Drug ineffective	135.46	15.07	466	11499	1044299	62432758
Dyspepsia	128.52	15.07	125	11840	102071	63374986
Weight decreased	115.15	15.07	195	11770	276603	63200454
Vaginal flatulence	102.78	15.07	34	11931	3259	63473798
Paradoxical drug reaction	102.67	15.07	36	11929	4116	63472941
Proctitis	86.11	15.07	34	11931	5407	63471650
Female genital tract fistula	75.33	15.07	34	11931	7525	63469532
Rectal haemorrhage	75.12	15.07	67	11898	48963	63428094
Vaginal discharge	71.96	15.07	35	11930	9163	63467894
Radiculopathy	71.10	15.07	34	11931	8577	63468480
Therapeutic product effect incomplete	68.34	15.07	100	11865	124956	63352101
Extrapyramidal disorder	67.91	15.07	38	11927	13246	63463811
Anuria	67.17	15.07	37	11928	12514	63464543
Drug ineffective for unapproved indication	59.13	15.07	50	11915	34013	63443044
Frequent bowel movements	57.74	15.07	42	11923	22980	63454077
Hepatic cirrhosis	50.70	15.07	40	11925	24694	63452363
Migraine	49.85	15.07	78	11887	103268	63373789
Oral candidiasis	44.87	15.07	36	11929	22762	63454295
Colitis ulcerative	44.67	15.07	38	11927	26053	63451004
Varices oesophageal	44.03	15.07	18	11947	3130	63473927
Abdominal pain	37.51	15.07	131	11834	293325	63183732
Arthropathy	33.25	15.07	3	11962	234789	63242268
Ear congestion	32.63	15.07	14	11951	2745	63474312
Hyperplastic cholecystopathy	31.03	15.07	7	11958	156	63476901
Infusion related reaction	30.83	15.07	109	11856	245412	63231645
Hypophosphataemia	29.00	15.07	21	11944	11405	63465652
Ligament sprain	26.87	15.07	21	11944	12779	63464278
Colitis	26.75	15.07	39	11926	48489	63428568
Systemic lupus erythematosus	26.28	15.07	4	11961	208914	63268143
Haematochezia	25.22	15.07	40	11925	53504	63423553
Electrocardiogram QT prolonged	24.70	15.07	42	11923	59488	63417569
Contraindicated product administered	23.54	15.07	6	11959	217642	63259415
Malaise	23.38	15.07	146	11819	415808	63061249
Abdominal discomfort	23.28	15.07	16	11949	320869	63156188
Synovitis	22.57	15.07	4	11961	186914	63290143
Withdrawal syndrome	22.39	15.07	23	11942	19974	63457083
Oligohydramnios	21.60	15.07	14	11951	6352	63470705
Ascites	21.39	15.07	32	11933	40696	63436361
Open reduction of fracture	21.01	15.07	8	11957	1154	63475903
Wound	20.82	15.07	3	11962	163260	63313797
Intraventricular haemorrhage neonatal	19.97	15.07	5	11960	176	63476881
Hypomagnesaemia	18.67	15.07	25	11940	28712	63448345
Hypoglycaemia neonatal	18.67	15.07	7	11958	968	63476089
Splenomegaly	18.58	15.07	16	11949	11141	63465916
Long QT syndrome	18.46	15.07	10	11955	3269	63473788
Joint swelling	18.17	15.07	21	11944	327645	63149412
Portal vein thrombosis	17.59	15.07	9	11956	2621	63474436
Hepatorenal failure	17.09	15.07	6	11959	688	63476369
Oesophageal varices haemorrhage	17.07	15.07	7	11958	1227	63475830
Diarrhoea	16.80	15.07	207	11758	715159	62761898
Gastrointestinal haemorrhage	16.77	15.07	43	11922	81133	63395924
Convulsive threshold lowered	16.68	15.07	5	11960	347	63476710
Bradycardia	16.40	15.07	40	11925	73187	63403870
Alopecia	16.28	15.07	24	11941	337512	63139545
Blood uric acid decreased	16.25	15.07	6	11959	795	63476262
Maternal exposure during pregnancy	15.91	15.07	11	11954	220051	63257006
Anaemia	15.84	15.07	102	11863	293328	63183729
Hypertrophy	15.57	15.07	5	11960	436	63476621
Aphthous ulcer	15.54	15.07	16	11949	13922	63463135
Cardio-respiratory distress	15.53	15.07	4	11961	158	63476899
Cardiogenic shock	15.50	15.07	18	11947	17914	63459143
Blood albumin increased	15.14	15.07	6	11959	963	63476094
Nausea	15.09	15.07	235	11730	854236	62622821

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic encephalopathy	94.72	17.10	45	5010	14640	34937236
Varices oesophageal	67.53	17.10	24	5031	3731	34948145
Ascites	47.35	17.10	45	5010	46526	34905350
Hepatic cirrhosis	47.08	17.10	30	5025	17284	34934592
Hepatic failure	46.27	17.10	39	5016	34492	34917384
Oesophageal varices haemorrhage	41.44	17.10	16	5039	3130	34948746
Hypoglycaemia	37.87	17.10	43	5012	54597	34897279
Lactic acidosis	34.19	17.10	33	5022	34739	34917137
Bradycardia	32.70	17.10	47	5008	75371	34876505
Portal hypertensive gastropathy	32.48	17.10	9	5046	618	34951258
Ammonia increased	30.03	17.10	14	5041	4355	34947521
Chronic hepatic failure	24.90	17.10	7	5048	507	34951369
Sinus arrest	23.45	17.10	9	5046	1731	34950145
Hyperkalaemia	22.71	17.10	38	5017	69351	34882525
Acute kidney injury	20.73	17.10	93	4962	304895	34646981
Inability to afford medication	17.68	17.10	7	5048	1463	34950413
Hypotension	17.67	17.10	71	4984	221578	34730298

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	193.03	14.39	74	14515	11222	79718577
Chronic sinusitis	186.25	14.39	75	14514	12951	79716848
Paraesthesia oral	150.70	14.39	74	14515	20397	79709402
Neovascularisation	146.54	14.39	36	14553	1209	79728590
Procedural pain	142.29	14.39	74	14515	23010	79706789
Dyspepsia	123.22	14.39	124	14465	108563	79621236
Vaginal flatulence	107.73	14.39	33	14556	2542	79727257
Weight decreased	93.88	14.39	203	14386	354995	79374804
Varices oesophageal	90.84	14.39	36	14553	5955	79723844
Paradoxical drug reaction	84.52	14.39	36	14553	7149	79722650
Hepatic cirrhosis	83.15	14.39	61	14528	34845	79694954
Female genital tract fistula	80.58	14.39	33	14556	5942	79723857
Proctitis	78.23	14.39	33	14556	6399	79723400
Vaginal discharge	76.71	14.39	34	14555	7429	79722370
Hepatic encephalopathy	75.77	14.39	50	14539	24116	79705683
Radiculopathy	74.33	14.39	35	14554	8789	79721010
Therapeutic product effect incomplete	65.25	14.39	103	14486	141542	79588257
Migraine	63.26	14.39	79	14510	87414	79642385
Rectal haemorrhage	60.19	14.39	72	14517	76228	79653571
Ascites	59.11	14.39	71	14518	75491	79654308
Anuria	53.02	14.39	38	14551	20925	79708874
Oesophageal varices haemorrhage	52.40	14.39	22	14567	4214	79725585
Extrapyramidal disorder	50.35	14.39	38	14551	22641	79707158
Drug ineffective for unapproved indication	46.53	14.39	52	14537	51186	79678613
Frequent bowel movements	43.52	14.39	39	14550	29500	79700299
Hypoglycaemia	41.50	14.39	70	14519	101524	79628275
Colitis ulcerative	39.97	14.39	40	14549	34702	79695097
Oral candidiasis	37.61	14.39	36	14553	29592	79700207
Hepatic failure	36.06	14.39	50	14539	61162	79668637
Infusion related reaction	35.96	14.39	108	14481	230129	79499670
Ammonia increased	34.64	14.39	20	14569	7615	79722184
Portal hypertensive gastropathy	34.31	14.39	12	14577	1402	79728397
Open reduction of fracture	33.02	14.39	8	14581	253	79729546
Ear congestion	32.27	14.39	14	14575	2905	79726894
Abdominal pain	31.62	14.39	148	14441	389421	79340378
Hyperplastic cholecystopathy	29.06	14.39	7	14582	216	79729583
Ligament sprain	28.65	14.39	22	14567	13442	79716357
Inability to afford medication	26.47	14.39	12	14577	2761	79727038
Bradycardia	26.47	14.39	69	14520	135488	79594311
Lactic acidosis	25.50	14.39	46	14543	70313	79659486
Portal vein thrombosis	23.12	14.39	14	14575	5813	79723986
Hepatic cancer	21.95	14.39	17	14572	10512	79719287
Torsade de pointes	21.78	14.39	22	14567	19290	79710509
Splenomegaly	20.46	14.39	22	14567	20732	79709067
Arthropathy	20.06	14.39	4	14585	177107	79552692
Intramedullary rod insertion	19.83	14.39	5	14584	187	79729612
Anaemia	19.67	14.39	144	14445	444871	79284928
Hyperkalaemia	19.11	14.39	55	14534	114343	79615456
Diarrhoea	18.64	14.39	244	14345	880245	78849554
Haematochezia	18.55	14.39	46	14543	87599	79642200
Oligohydramnios	18.37	14.39	10	14579	3402	79726397
Sinus arrest	17.81	14.39	10	14579	3612	79726187
Hypophosphataemia	17.71	14.39	20	14569	19893	79709906
Hypoglycaemic unconsciousness	17.55	14.39	7	14582	1176	79728623
Gastrointestinal haemorrhage	17.39	14.39	63	14526	147656	79582143
Gastric varices	16.88	14.39	6	14583	735	79729064
Malaise	16.49	14.39	149	14440	489720	79240079
Hypoglycaemic seizure	16.26	14.39	6	14583	818	79728981
Colitis	16.07	14.39	39	14550	73268	79656531
Insurance issue	15.91	14.39	11	14578	5722	79724077
Large intestine polyp	15.30	14.39	15	14574	12693	79717106
Febrile neutropenia	15.19	14.39	12	14577	230987	79498812
Chronic hepatic failure	15.02	14.39	6	14583	1013	79728786
Electrocardiogram QT prolonged	14.65	14.39	43	14546	90343	79639456
C-reactive protein increased	14.43	14.39	3	14586	129024	79600775

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C07AA12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, non-selective
ATC	C07BA12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, non-selective, and thiazides
FDA MoA	N0000000161	Adrenergic beta-Antagonists
FDA EPC	N0000175556	beta-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D000319	Adrenergic beta-Antagonists
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013565	Sympatholytics
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:66991	sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Angina pectoris	indication	194828000
Thyrotoxicosis	off-label use	90739004	DOID:7997
Mitral valve prolapse	off-label use	409712001
Essential tremor	off-label use	609558009	DOID:4990
Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia	off-label use
Myocardial Reinfarction Prevention	off-label use
Prevention of Bleeding Esophageal Varices	off-label use
Migraine Prevention	off-label use
Anuria	contraindication	2472002	DOID:2983
Bronchospasm	contraindication	4386001
Hypercholesterolemia	contraindication	13644009
Complete atrioventricular block	contraindication	27885002
Depressive disorder	contraindication	35489007
Hyperuricemia	contraindication	35885006	DOID:1920
Anaphylaxis	contraindication	39579001
Hypokalemia	contraindication	43339004
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Oliguria	contraindication	83128009
Pulmonary emphysema	contraindication	87433001
Cardiogenic shock	contraindication	89138009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypomagnesemia	contraindication	190855004
Partial atrioventricular block	contraindication	195039008
Decompensated cardiac failure	contraindication	195111005
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Raynaud's phenomenon	contraindication	266261006
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Right ventricular failure	contraindication	367363000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.57	acidic
pKa2	9.31	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	6.90	IUPHAR	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	8.60	IUPHAR	CHEMBL
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	ANTAGONIST	Ki	6.30	IUPHAR

External reference:

ID	Source
4017603	VUID
N0000145983	NUI
D00432	KEGG_DRUG
4017603	VANDF
C0027302	UMLSCUI
CHEBI:7444	CHEBI
CHEMBL649	ChEMBL_ID
DB01203	DRUGBANK_ID
D009248	MESH_DESCRIPTOR_UI
39147	PUBCHEM_CID
554	IUPHAR_LIGAND_ID
3875	INN_ID
FEN504330V	UNII
151549	RXNORM
2018	MMSL
31	MMSL
5143	MMSL
d00018	MMSL
001854	NDDF
387482003	SNOMEDCT_US
82896009	SNOMEDCT_US
220045-89-6	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nadolol and Bendroflumethiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0115-5311	TABLET	40 mg	ORAL	ANDA	25 sections
Nadolol and Bendroflumethiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0115-5322	TABLET	80 mg	ORAL	ANDA	25 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0028	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0028	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1132	TABLET	80 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1132	TABLET	80 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1171	TABLET	40 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1171	TABLET	40 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8004	TABLET	20 mg	ORAL	ANDA	21 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8004	TABLET	20 mg	ORAL	ANDA	21 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8005	TABLET	40 mg	ORAL	ANDA	21 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8005	TABLET	40 mg	ORAL	ANDA	21 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8006	TABLET	80 mg	ORAL	ANDA	21 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8006	TABLET	80 mg	ORAL	ANDA	21 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7070	TABLET	20 mg	ORAL	ANDA	18 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7071	TABLET	40 mg	ORAL	ANDA	18 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-686	TABLET	20 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-686	TABLET	20 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-687	TABLET	40 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-687	TABLET	40 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-688	TABLET	80 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-688	TABLET	80 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-799	TABLET	40 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-800	TABLET	80 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-802	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	23155-730	TABLET	20 mg	ORAL	ANDA	12 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	23155-731	TABLET	40 mg	ORAL	ANDA	12 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	23155-732	TABLET	80 mg	ORAL	ANDA	12 sections
Corgard	HUMAN PRESCRIPTION DRUG LABEL	1	27505-100	TABLET	20 mg	ORAL	NDA	20 sections
Corgard	HUMAN PRESCRIPTION DRUG LABEL	1	27505-101	TABLET	40 mg	ORAL	NDA	20 sections